Search Results - "Pandit-Taskar, Neeta"

Summary of the 2024 Update of the North American Guidelines for Pediatric Administered Radiopharmaceutical Activities.

Authors: Treves, S. Ted Fahey, Frederic H. Valencia, Valentina Ferrer et al.

Source: Journal of Nuclear Medicine. Mar2026, Vol. 67 Issue 3, p341-342. 2p.

Theranostic Intratumoral Convection-Enhanced Delivery of ¹²⁴I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry.

Authors: Pandit-Taskar, Neeta Zanzonico, Pat B. Grkovski, Milan et al.

Source: Journal of Nuclear Medicine. Sep2024, Vol. 65 Issue 9, p1364-1370. 7p.

Phase 1 study of intraventricular ¹³¹I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.

Authors: Kramer, Kim Pandit-Taskar, Neeta Kushner, Brian H. et al.

Source: Journal of Hematology & Oncology. 11/12/2022, Vol. 15 Issue 1, p1-12. 12p.

2024 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities.

Authors: Treves, S. Ted Fahey, Frederic H. Ferrer Valencia, Valentina et al.

Source: Journal of Nuclear Medicine Technology. Sep2025, Vol. 53 Issue 3, p193-197. 5p.

Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with ¹³¹I-omburtamab for leptomeningeal disease.

Authors: Prasad, Kavya Serencsits, Brian E. Chu, Bae P. et al.

Source: EJNMMI Research. 7/31/2024, Vol. 14 Issue 1, p1-8. 8p.

Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.

Authors: Landau, Heather Pandit-Taskar, Neeta Hassoun, Hani et al.

Source: Leukemia & Lymphoma. Feb2012, Vol. 53 Issue 2, p275-281. 7p. 3 Charts, 2 Graphs.

Determination of the Intralesional Distribution of Theranostic ¹²⁴I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma.

Authors: França Velo, Alexandre Giantini Larsen, Alexandra Humm, John L. et al.

Source: Journal of Nuclear Medicine. Jun2025, Vol. 66 Issue 6, p886-891. 6p.

Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins.

Authors: Strigari, Lidia Schwarz, Jazmin Bradshaw, Tyler et al.

Source: Journal of Nuclear Medicine. May2025, Vol. 66 Issue 5, p748-756. 9p.

Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.

Authors: Pandit-Taskar, Neeta Iravani, Amir Lee, Dan et al.

Source: Journal of Nuclear Medicine. 2021 Supplement, Vol. 62, p60S-72S. 13p.

SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.

Authors: Rowe, Steven P. Shuch, Brian M. Ball, Mark W. et al.

Source: Journal of Nuclear Medicine. Dec2025, Vol. 66 Issue 12, p1863-1870. 8p.

Survey of Clinical Protocols for the Use of ¹⁷⁷Lu-PSMA-617 in the United States.

Authors: Kuo, Phillip H. Covington, Matthew F. Lee, Daniel J. et al.

Source: Journal of Nuclear Medicine Technology. Sep2024, Vol. 52 Issue 3, p208-211. 4p.

First-in-human imaging with ⁸⁹Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting.

Authors: Pandit-Taskar, Neeta Postow, Michael A. Hellmann, Matthew D. et al.

Source: Journal of Nuclear Medicine. Dec2019, Vol. 60 Issue 12, Preceding p1-1. 39p.

Biodistribution and Dosimetry of Intraventricularly Administered 124I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.

Authors: Pandit-Taskar, Neeta Zanzonico, Pat B. Kramer, Kim et al.

Source: Journal of Nuclear Medicine. Dec2019, Vol. 60 Issue 12, p1-31. 31p. 1 Color Photograph, 1 Diagram, 5 Charts, 2 Graphs.

Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.

Authors: Herrmann, Ken Giovanella, Luca Santos, Andrea et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jun2022, Vol. 49 Issue 7, p2300-2309. 10p. 1 Chart.

Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.

Authors: Pandit-Taskar, Neeta O'Donoghue, Joseph Beylergil, Volkan et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Nov2014, Vol. 41 Issue 11, p2093-2105. 13p.

A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.

Authors: Kalidindi, Teja Muralidhar Lee, Sang-Gyu Jou, Katerina et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jul2021, Vol. 48 Issue 8, p2642-2651. 10p. 1 Diagram, 1 Chart, 2 Graphs.

IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab—pharmacokinetic modeling to optimize therapeutic index.

Authors: Yerrabelli, Rahul S. He, Ping Fung, Edward K. et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Apr2021, Vol. 48 Issue 4, p1166-1177. 12p. 1 Diagram, 3 Charts, 7 Graphs.

Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.

Authors: Krebs, Simone O'Donoghue, Joseph A. Biegel, Evan et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. 2020, Vol. 47 Issue 13, p3047-3057. 11p. 3 Color Photographs, 2 Charts, 2 Graphs.

Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: α Therapy with ²²³Ra-Dichloride.

Authors: Pandit-Taskar, Neeta Larson, Steven M. Carrasquillo, Jorge A.

Source: Journal of Nuclear Medicine. Feb2014, Vol. 55 Issue 2, p268-274. 7p. 1 Color Photograph, 2 Diagrams, 5 Charts, 1 Graph.

Radiation Safety Considerations and Clinical Advantages of α-Emitting Therapy Radionuclides.

Authors: Serencsits, Brian Chu, Bae P. Pandit-Taskar, Neeta et al.

Source: Journal of Nuclear Medicine Technology. Dec2021, Vol. 49 Issue 4, p1-20. 20p.